VLG manages a growing portfolio of its own healthcare brands focused on ageing consumers, supported by its integrated product development and manufacturing model. Sold without prescription, these brands address common ailments of ageing, cater for a population with raised expectations of quality of life and longevity, and travel well across international markets. A low risk high growth investment story.
VLG's strong H1 revenue growth has continued through H2, and a strong Euro confirms FY2016 revenues of not less than £14m, signalling a >50% increase over FY2015. In addition, a strong order book for Development & Manufacturing suggests that the current buoyant business momentum continues into 2017.
The significant growth plans for UltraDEX are well-advanced based on a completed integration, launch preparations in international markets and a new UK Sales Director.
Strengthened Euro improves on £ expectations. A FY2016 revenue result of 'not less than £14m' beats our forecast of £13.7m and is part-driven by a stronger €uro and in larger part by organic growth.
UltraDEX in H2. UltraDEX revenues rose in Sept/Oct, through increased store listings, supported by planned advertising and efforts to broaden customer awareness. October saw the first of three international launches - Spain.
Order book build bodes well for 2017 outlook. Jan '17 orders for Development & Manufacturing business are >45% ahead of actual revenues in Jan '16. Future order flow should help support this positive growth indicator. A UK Sales Director anticipates a sharper market focus on UltraDEX in 2017 as well as opportunities to implement more brand launches in the UK market.
